Indonesia is a mega-biodiversity country with a high number of herbal plants, in particular Murraya koenigii and Nigella sativa. Their extract reported having activities as anti-cancer, including lung cancer. It is one type of cancer which has a high mortality rate. One of the important receptors for lung cancer is Kirsten rat sarcoma virus (KRAS) which grows in lung adenocarcinoma, a subtype of Non-small Cell Lung cancer (NSCLS). Recent treatment such as sotorasib could cause side effects and serious adverse effects, thus an alternative treatment is needed. The currently developed method for skrining new compounds targeted KRAS receptors is molecular docking. This study aims to find candidates for several ligands that have interactions with the KRAS receptor in lung cancer to have better activity than sotorasib. We carried out an in silico study by docking candidate ligands with the KRAS receptor using the MOE 2015 V.10 application. 5 out of 10 candidate compounds have interactions through hydrogen bonding with the KRAS receptor. Dithymoquinone is the compound with the lowest Gibbs free energy, which is -12.3107 joules/kg.mol, and has the strongest bond. Dithymoquione derived from the Nigella sativa (Black cumin) corresponds to sotorasib for ligand-interaction when docked with the KRAS G12C receptor. This finding could be a potential new drug for lung cancer. However, further studies, such as in vitro, in vivo and clinical trials need to be conducted to confirm the activities, safety and efficacy of the new drug.